The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease

Status:
Completed

Trial end date:
2006-01-01

Target enrollment:

Participant gender:

To determine the effects of the NMDA antagonist, CP-101,606, in subjects with Parkinson's Disease

Phase 2

Pfizer